Advancing preclinical cancer models to assess clinically relevant outcomes

Abstract Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer’s Collection of articles addressing ‘ Advances in pre-clinical cancer models’ towards relivable outcomes at the preclinical stage.